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Abstract 
1995 is set to be a key year for the rules governing medical data in Europe: the Council 
of Europe is in the process of approving the final draft of a new Recommendation on the 
Protection oflVledical Data while the member states of theEuropean Union have adopted 
a directive on data protection. 
The paper wiI1 present: 
l. some of the interim results of the University of11alta~s LEXIlvfP 9 Project reporting 
on the extent to which the Council of Europe's 198 I Recommendation on Data 
Protection in the lvledical sector was actually implemented in the 34 member states 
of the Council of Europe. This project includes a comparative analysis of specific 
rules, relevant case-law and other relevant regulations; 
11. an ovenl iew of the new Council of Europe Recommendation on Medical Data, 
specifically addressing confidentiality, access to data and information integrity; 
iii. the relevance of the ED Directive; 
I. Trends in Rule-Making 
1.1 iVew Rules: Trendy Rule-making 
The advance in medical technologies would appear to bring with it a proportional 
increase in the legal rules governing various areas of the practice of medicine. Europe 
seems to be moving towards a bumper crop of new rules in the medical field. The Council 
of Europe has at least two different sets of mles in various stages of finaIisation: 
1. The draft Recommendation on the Protection of.L'v1edical Data (Rec96 [1 ])prepared 
by the Project Group on Data Protection (C]-PD also known as the Committee of 
E.xperts on Data Protection); 
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u. The draft Bioethics Convention (Dra ft Convention for the protection of Human 
Rights and Dignity of the I-Iuman Being with regard to the application of Biology and 
Nledicine: Bioethics Convention) prepared by the Steering Committee on Bioethics 
(CDBI previously CABBI or ad hoc Committee of Experts on Bioethics) 
while the European Union has, on the 24th July 1995, adopted a new draft directive on 
Data Protection, which has been the best part of five years in the making. The 15 
member-states of the ED should bring their legislation in line with the Directive by no 
later than 24th July 1998. 
Indeed, these new sets of rules all share a pedigree common to much consensus rule-
making in Europe: each has been through several years of legal wrangling in a process 
which will have different consequences dependent on the nature ofthe legal instnunent 
involved. 
The Council of Europe initiatives have to be seen in the context of GVO previous 
landmarks in European law; the European Convention on Human Rights andFundamcntal 
Freedoms (1950) and the European Data Protection Convention (Convention 108 
[2])1981. These two Conventions mark the formal international agreement establishing 
(or, perhaps, merely recognizing) a fundamental right to private and family life [3]and 
consequently the implied right to protection of personal data as part of the attempt to 
preserve the informational privacy which forms an integral part of such a right "to private 
and family Efe ll • 
1.2 Old Rules: Actual trends in Rule Adoption 
16 countries have ratified the Data Protection Convelltion, 13 of these being members 
of the EU together with Iceland, Norway and Slovene. Italy and Greece are the only EU 
member states not to have ratified this Conventioll) but now face the mandatory 
implementation of comparable data protection standards in accordance with the ED 
directive [4]. 5 other countries have signed the Convention with the declared intention 
of ratifying it in the near future. 
Rec96 was developed ben:veen 1990 and 1995 and will supersede a previous 
Recommendation on the Protection of Automated Nledical Data Banks R(81)1 which 
dates from January 1981. 
It is important at this stage to dearly distint,Juish between the legal nature ofa Treaty such 
as the Conventions on Human Rights and Data Protection and a non-binding instnllnent 
such as a Recommendation. vVl1ereas trc;Hies are binding upon signatory states on 
ratification, a Recommendation is issued by the Council of Europe's Committee of 
A;Iinisters to the Governments ofNlember States as a policy document drafted with a view 
to harmonization of the various European legal systems. Although technically non-
binding upon the 37 member states of the Council of Europe, these Recornmendations 
exert considerable intluence on developments within the states and are taken into account 
by the legislators, Governments and Data Protection enforcement agenCIes when 
formulating or implementing relevant data protection rules. 
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The drafting of the Recommendation on the Protection of l\ledical Data was also 
influenced by the drafting of the Bioethks Convention. The latter attempts to extend 
legal protection and enforceability to a number of principles: i) respect for the dignity of 
the person (including a ban on all forms of discrimination); ii) inviolability (protection of 
individual integrity); iii) security of both human genetic material and its information; iv) 
inalienability (including prohibition of all commercial agreements concerning the human 
body and its organs); v) assurance of the testing and quality of services (through an 
assertion of public responsibility regarding the application of the biomedical sciences [5] 
\\Thile the Bioethics Convention is undoubtedly of considerable interest to geneticists 
and related disciplines, from the point of view of medical informatics, the greatest interest 
lies in the specifics of Rec96. The European Union Directive is more important for the 
renewed emphasis that it brings to the notion of data protection rather than for any great 
sense of jurisprudential innovation. To a considerable extent, the EU Directive replicates 
the principles of the Council of Europe's Data Protection Convention, although it does 
extend the application of these principles to many forms of manual as well as automated 
personal data. , 
Both the Council of Europe Convention on Data Protection and the ED Directive are 
generic legal instruments covering the whole area of personal data, and both documents 
refer to medical data as sensitive data meriting special safeguards[7] Beyond the 
esta blishment of this basic character of special status for medical data, neither of these two 
instruments provides specific t,ruidelines for the application of data protection principles 
to the medical sector. The details of the sectoral approach are left up to the pertinent 
Recommendations, previously Recommendation R(81) 1 and now the new 
Recommendation (Rec96).[8] 
Before proceeding to examine the import of the new Recommendation on the Protection 
of 1\ledical Data, it is useful to attempt to take stock of the sihlation obtaining in Europe 
in 1995, immediately prior to the adoption of this new Recommendation. In this way, it 
is possible to attempt to gauge the progress of the protection of medical data in Europe 
since the adoption of the 1981 Recommendation on Automated Medical Data Banks. 
Project LEXIMP 9 within the University of lYralta's Law & Informatlon Technology 
Research Unit set out to find an answer to the question: vVhat has the passage of 15 years 
since the opening for signature of the Council of Europe's Data Protection Convention 
and its adoption of its first recommendation on medical data meant in real terms for the 
protection of data ty--pically collected in the health care environment? After all, the 
authors had, on a number of different occasions within different European countries) 
occasionally met the odd official responsible for implementing data protection in the 
medical sector only to be told that "Yes, we are aware of the existence of the 
Recommendation. It's in my bottom right hand drawer ... but I've never really read it 
[8] !llFaced with this response on the one hand and the reality of a situation where the 
Conncil of Europe as an organization, and a good number of the member states, were 
expending much effort in formulating an entirely new recommendation, it appeared 
interestlngto investigate to what extent the Erst Recommendation had been implemented 
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within Europe. 
Thus, in August 1994, a questionnaire was distributed to the pertinent authorities within 
the (then) 32 member states of the Council of Europe. Of these, a response was received 
from 22 countries, a synopsis of which is represented in Figure 1 attached. 
It would appear from the response that the issue of medical data has been tackled either 
by specifIc sections within a generic national law on Data Protection and/or specific 
regula tions drawn up with the specific purpose of addressing many of the concerns which 
were originaHy raised in Convention 108 and/or Recommendation R(8l)!. 
The following countries have specific sections mentioning medical data in their generic 
Data Protection Acts: Lmcembourg; Denmark; Switzerland; Hungary; Italy (Bill); Portugal; 
Netherlands; Iceland; Czech Republic, Germany. 
The following countries enacted specific rebrulations aimed at sectoral coverage of 
medical data: 
L U.K. 
ii. Luxembourg 
lll. Denmark 
IV. Switzerland 
v. Hungary 
VL Italy 
~/lL Netherlands 
YIll. Iceland 
IX. Finland 
x. Austria 
XL Germany 
The immediate aim of the LEXL'vlP9 project was not a detailed jurisprudential analysis 
of the implementation of various legal principles in different European states, (although 
in the end it netted sufficient material to carry out a section-by-section analysis at a level 
of detail which would pack several volumes of comparative analysis). 
The immediate LEXILVIP9 objective [9] coinciding with the requirement for this present 
study, is to obtain an overview, a snapshot of the pan-European position in medical data 
protection based on a comparative analysis of the progress achieved in national legislation 
since 1981. Given this aim, rather than going through the national laws on a nation-by-
nation, section-by-section basis, the approach llsed will start off by constructing an 
achievement matrix on the framew'ork of the 1981 Recommendation. In this way, it is 
possible, a t a glance, to assess the extent to which the first .Nledical Data Protection 
Recommendation was implemented across Europe. The matrix was constructed by 
examining the extent to which (if any) the measures recommended in the principles of 
Recommendation R (81)1 were incorporated into the legal provisions of the 22 countries 
who responded to the LEXLvlP 9 questionnaire. This matrix is reproduced in Figure 2. 
After nearly fifteen years from the launch of Recommendation R(81)l on automated 
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Tflble 1'epnlenting results ofquestiontlire (4j 
medical data banks, a careful examination of Figures 1 and 2 would support the following 
conclusions: 
L iVlany (9) countries have a section or two referring to medical data in their generic data 
protection law . .iVIost of these are in a sensitive data context and appear to be related 
to the concerns expressed in article 6 of Convention 108. 
11. One should not be misled by a list of eleven countries who have enacted legislation 
aimed specifically at medical data. Of these, 7 countries have only a couple of sections 
relating to medical data and these are not necessarily capable of being mapped onto 
the safeguards originally proposed in R(Sl)!. 
iii. Only 3 countries, Luxembourg, Denmark and Finland, and, to a lesser extent, the 
U.K. appear to have made the legislative effort to incorporate a majority ofR(Sl)l's 
rules into i1.<; own laws. 
lV. Only 7 conrt cases (relating to medical data) in 5 countries have been reported; 
This state of affairs may be explained as being the result of one or a combination of the 
following: 
a. R(Sl)l spelt out rules for a technology that was rapidly becoming obsolete; 
b. R(Sl)l should have included rules about other aspects of data protection in the 
medical sector; 
c. R(8 I) 1 was not sufficiently publicized; 
d. Protection medical data is not very high on the scale of legislative priorities; 
e. there are in practice few problems with data protection in the medical sector and the 
problems are more perceived than real; 
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Figure 2: Implementation of R(8J 0 1 (old rec07mntn'zdtltion) on tttltoma.ted medical data banks (2) 
1.3 Actual Trends: lVew Rules not yet adopted ... but outstrip old 
The LEXLvlP9 research is not sufficiently far advanced. enough to establish the precise 
cause for the results obtained so far. Wnat is certainly interesting is that, when pursuing 
the theory of obsolete lin adequate regulation, anothermatrixwas drawn up, that reproduced 
in Figure 3, investigating the conformity of existing laws with the forthcoming 
Recommendation on protection of 1-1edical Data (i.e. Rec96). This showed that more 
countries had provisions in their laws in line with the new recommendation (before it is 
formally adopted!) than there are countries with provisions in line with R(8l)l, fifteen 
years after its au.option~ Times have obviously been moving faster than the provisions of 
R(81)1. 
This also seems to have been the gut feeling of the Council of Europe~s Committee of 
Experts on Data Protection which, without the benefit of the 1995 results of the 
LEXLvIP9 project, in 1990 deemed R(Sl)l as being in need of overhaul and proceeded 
to set up a working party encharged with the task of writing the new Recommendation, 
to which it is now opportune to turn our attention, dearly emphasizing that, since it was 
adopted by the Committee ofiVlinisters subject to the opinion of the CDSP, certain parts 
[10] of the Recommendation may possibly be amended before final adoption. 
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Figure 3: Conformity laws with New Recommandtuinl1 data 
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2. New Rules: Overview 
2. I Scope and purposes 
The underlying scope and purpose of the new medical data recommendation (Rec96) 
vanes from R (81) 1 or any subsequent sectoral recommendations. 
In the preliminary discussions leading to Rec96, the concept of "medical records" in R 
(81) 1 was considered to be overly restrictive in the context of electronjc data processing. 
It was realized that the new recommendation had to go beyond the discreet relationship 
betv{een the doctor and his patient, so as to cover any person likely to keep medical data 
(11 J 
"Aware of the increasing use of automatic processing of medical data by information 
systems, not only for medical care, medical research, hospital management and public 
health [12] but also outside the health care sector [131 a wider ranging protection was 
required. 
Furthermore, the drafters of Rec96 were aware of the fact that .Article 6 of Convention 
108 required that "appropriate safeguards" provided for by law are required for the 
processing for whatever purpose of medical data. 
There were however two approaches to this situation within the drafters: one approach 
favored a wide all encompassing provision and the other approach suggested that each 
purpose of medical data processing fa lling within the scope of the recommendation be 
listed. 
At a later certain experts wished to restrict the scope of the Recomrnenda tion since, 
they contended, it would be impossible to apply the same provisions to medical data 
which, although all sensitive, do not have the same consequences for the respect of the 
rights and freedoms of the data subjects when they are processed. On the other hand, 
other experts insisted on a high level of protection, to ensure that medical data would be 
protected regardless of the method of processing or the person in charge. Two 
alternatives were therefore proposed and the final decision of the Committee ofl\1inisters 
was in favor of an approach wherein Rec96 applies to a.ll medical data, both within and 
outside the health sector. (The issue has been re-opened recently by the CDSP and a final 
decision is to be taken over the next few months). 
Given this new raison a suitable definition of rnedical data had to be formulated. 
2.2 lvlediCttl DItta 
Indeed one of the major innovative features of the new medical data recommendation is 
the meaning being attributed to the term "medical data". 
The importance of the new detlni60n lies on two counts: 
(i) it gives a definition which was lacking in previous legal documents 
Oi) it is a ddinition verging on "breakthrough" status since it also incorporates a usable 
(though not deflnitive) definition of 'genetic data' 
Legal inue:; 31) 
Recommendation R (S1) t did not provide a definition of medical or health data. 
lIowever, the Explanatory Memorandum of R(S1) 1 at point 21 explains that "the term 
"medical data" includes information concerning the past, present and future, physical or 
mental health of an individual, as well as related social or administrative information 
[14].There were at least two nove] difficulties in finalizing this definition: whether one 
could define genetic data and whether this definition (if present) could, strictly speaking, 
be included ·within the notion of medical data. 
Although, at one stage, it was noted that no definition of Hgenetic data" seemed to have 
been generally accepted. in Recommendation No. R(92)3 all genetic testing and screening 
for health care purposes, the following footnote appeared: ('Genetic testing and 
screening can be carried out at different levels, such as on chromosomes, on genes (DNA)) 
proteins, organs or a given individual, which can be complemented aspects of the family 
history." It was agreed to follow the same procedure a footnote was appended to the 
definhion of "medical data", which, without conflicting with the footnote in 
Recommendation R(92)3, was less detailed. 
It was later felt that the reference to the definition of "genetic data)) should not be left to 
a mere footnote but that a suitable definition should he included in the main text of the 
Recommendation. N1any meetings later, the following definition took shape: "The 
expression "medical data" refers to all personal data concerning the health of an 
individual. It refers ~}lso to data which have a manifest and close link with health as well 
as to genetic data [15j. 
2.3.1 collection and/or processing: position ofd4ta handler 
Due to the sensitive nature of medical data only specific categories of people should be 
allowed to collect and process data. One of the arguments long advanced by doctors is 
that they do not need data protection because as doctors they are subject to the rules of 
medical confidentiality or medical secrecy as it is called in some countries (le secret 
medical). 
The point is that medical data is today handled by many other people apart from nurses 
and doctors and these may include derks, data input operators, social security advisers, 
insurance agents, etc. all of whom may have legitimate interests to process medical data 
and none of whom are subject to the same nlles of medical confidentjality as doctors. It 
\!,tas therefore seen that this new recommendation on medical data would be introducing 
an additional safe!:,ruard by mandating comparable rules of confidentiality on everybody 
handling health-care data irrespective as to whether he is a health care professional ornot. 
i~" currently drafted, the second paragraph of principle 3.2 of Rec96 underlines that in 
principle medical data should be collected and processed only by, or on behalf of, 
healthcare professionals subjected to TIlles of confidentiallty [16]. 
316 Proceedings A1'vllCE 9 S 
2.3.2 Purpose ;,peciflcatian 
The sensitive nature of medical data, together with the requirement of appropriate 
safebTUards, make it even more important that the purposes are defined. The way in which 
the legitimate purpose is specified may vary in accordance with national legislation. 
2.33 Pur pores within permitted limits 
Principle 4.3 of Rec96 lays down when medical data may be collected: 
a. if required under a legal obligation 
b. if provided for by law for the purposes of 
i. the protection or the promotion of public health, or [17] 
ii. the safeguarding of vital interests of the data subject or a third person, or [18] 
iii. subject to principle 4.7, the prevention of a real danger or the suppression of a 
specific criminal offense (191 
In the case of "generic data" the drafters of the recommendation consider it as an even 
more sensitive area of medical data ~md required that "for the purpose of a judicial 
procedure or a criminal investigation" processing should only be allowed only if specific 
appropriate safeguards are enacted in a speciflc law. Furthermore genetic data "should 
only be used to establish whether there is a genetic link in the framework of adducing 
evidence, to prevent a real danger or to suppress a specific criminal offense. In no case 
should they be used to determine other characteristics which may be linked genetically 
[20] 
c. if authorized by law for preventive medical purposes or for diagnostic or therapeutic 
purposes with regard to the data subject or a relative in the genetic line [21J. 
d. if the data subject or his legal representative has given his consent. (Apart from any legal 
obligation or provision, medical data may also be collected and processed if the data 
subject - or his legal representative - has given his consent. The drafters of the 
Recommendation were aware that, from the point of view of protection of medical data, 
consent of the data subject gives fewer guarantees than legal obligations or legal 
provisions which - in virtue of Article 6 of the Convention - should be accompanied by 
appropriate safeguards.) 
The issue of consent is dealt with in Chapter 6 of Rec96. There are several instances in 
the course of Rec96 where the data subject mayor is expected to give his consent. 
2.3.4. Special attention: 
2.3.4.1 "genetic data lj 
Due to the specific sensitive nature of genetic clata, further to all the conditions for 
collection and processing applicable to medical data, a number of additional conditions 
have to be respected in the collection and processing of genetic data. 
Indeed "Genetic data collected and processed forsdentific research, preventive treatment, 
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diagnosis or treatment of the data subject, should only be used for these purposes or to 
allow the data subject to take a free and informed decision on these matters. [22} 
The problems that arise here are linked to whether a data subject should he put in a 
position to submit his genetic data to obtain some benefit or whether irrespective of his 
su bmission of data the benefitwould still be offered to him. The Explanatory Memorandum 
points out (23) that ('the drafters of the Recommendation emphasized that a candidate for 
employment, an insurance contract or other services or activities should not be forced to 
undergo a genetic analysis, by making the employment or the insurance dependent on 
such analysis, unless such dependence is explicitly provided for by law and the analysis is 
necessary for the protection of the data subject or a third party (e.g. work with dangerous 
substances). " 
Principle 4.8 attempts to limit the collection and processing of genetic data for such other 
purposes by requiring that "in principle, [collection and processing should) only be 
permitted for health reasons and in partic.:ular to avoid any serious prejudice to the health 
of the data subject or third par6es." 
Furthermore, when such collection and processing is required in "order to predict [the 
occurrence or potential occurrence of an] illness" there must be proof "of an overriding 
interest or of a collective interest (24) and subject to appropriate safeguards defined by 
domestic law." 
It is important to remember at this stage that principle 6.3 of Rec96 requires that "the 
results of any genetic analysis should be formulated within the limits of the objectives of 
the medical consultation, diagnosis or treatment for which consent was obtained." 
2.3.4.2 unborn [biM 
Another innovation introduced by Rec96 is that found in principles 4.4 and 4.5 which 
provide for data referring to unborn children: 
Principle 4.4 ulvledical data concerning unborn children should be considered as personal 
data. In respect of its medical data, an unborn child is considered to enjoy a protection 
comparable to the protection of a minor." 
Principle 4.5 "Unless otherwise provided for by domestic law, the holder of parental 
responsibilities may act as the person legally entitled to act for the unborn child as a data 
subject [25]. 
Thus the person/s expected to act for the unborn child would depend in reality on the 
position established in the country of implementation. For example, if the mother is 
considered to be responsible for the unborn child then it is the mother who would be 
responsible. On the other hand, in the case of certain Civil law countries \\'here a tutor 
or curator is appointed (e.g. "cnratore del ventre"), then the tutor or curator would be the 
person responsible. 
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2.4 Collection and Processing 
2.4.1 Collection from data subject unlcj]" conditions in principle 4.2 are satisfied 
"Nledical data shall in principle be obtained from the data subject." [26J. There may, 
however, be circumstances where the data cannot be obtained from the data subject and 
other sources need to be consulted. Other sources may be used only if the provisions in 
chapters 4 (collection and processing), 6 (consent) and 7 (communication) and "if this is 
necessary to achieve the purpose of the processing or if the data subject is not in a position 
to provide the data." 
2.4.2. information for data subject 
The collector of the data should inform the data subject at the moment of collection of 
a number of elements listed in principle 5.1.[27] is obvious that such information is 
indispensable when the data subject is required to give his infonned consent. [28] 
If such data is being collected from the data subject then he should be informed 
individually. This requirement [29] is one of the most contested by collectors of data. 
Collectors of data claim that this requirement to inform individually is too time 
consuming. On the other hand, the data subject's right to be informed of the purposes, 
use and existence of his data has always been regarded as requiring such a requirement. 
There are instances where such requirement to inform has been interpreted widely. A 
mere notice of information written on some part of a collection sheet or on a public notice 
has been considered to suffice. 
vVhere the data is being collected from other sources then the data subject is to be 
informed as soon as possible "unless this is manifestly unreasonable or impracticable, or 
unless the data subject has already received the information." [30] 
The drafters of the recommendation recognized the fact that there are certain medical 
situations where the data subject should not or cannot be informed. In the spirit of Article 
9 of Convention 108 which allows a number of restrictions and exceptions to the data 
protection principles established in the Convention, the drafters of the recommendation 
have allowed a number of derogation's to the duty of information. 
2.4.3 Communictttioll 
Communication of data to other sources not contemplated in the purpose of collection 
is, in principle, not permitted in the field of data protection. This is even more so in the 
case of medical data [3 IlHowever there are certain situations where such communication 
can be permitted. Indeed principle 7.2 (32] holds that "medical data may be cOlrununicated 
if they are relevant and if" they satisfy a number of conditions namely: (i) specific 
provisions in domestic law; (ii) fall within the purpose for which data was collected; (iii) 
is required for the "public good"; (iv) the data subject has given his consent. 
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2.4.4 Rights 0/ the data subject are respected 
The Hind ividual participation principle" is one of the most important data protection 
principles. An individual should have the right to know about the existence of a file 
conta1n]n g data on himself, have access to it and furthermore can ask for the rectification 
or erasure of data pertaining to him. This principle poses a number of problems in the 
case of medical data. It has been argued that a normal data subject would be incapable of 
understar .. dingnledical data. Indeed, the recommendation requires that such information 
where given should be made "accessible in understandable form." Another issue arises 
where, wl1en rendering accessible one's data, other third party's medical data can be 
revealed. This is especially the case for genetic data, where one's generic code necessarily 
reflects that of other consanbrlline or uterine kin. In such cases [33] the drafters of the 
reconune.t1dation have pennjtted derogations from the right of access and rectifIcation of 
individual data. 
The recofl1mendation goes a step further then the normal situations of rights of access and 
rectification. The drafters have identified the situation where, especially after genetic 
testing, wllere unexpected findings can result, that is, findings which were not necessarily 
those for '-"hlch the test was made, for example, in the course of testing for the presence 
of a particular disease (genetic screening) one finds that in reali ty his parents are not the 
ones he bas been accustomed to recognize as such. Should a data subject still have the 
right to access and ask for rectification of such unexpected findings? Principle 8.4 holds 
that "the person subjected to genetic analysis should be informed of unexpected findings 
[only] if the following conditions are met: 
a. domestic law does not prohibit the giving of such information; 
b. the person himself has asked for this information; 
c. the information is 110t likely to cause serious harm 
1. to his/her health, or 
ii. to his/her consanguine or uterine kin, to a member of his/her social family, 
or to a person who has a direct link \vith his/her genetic tine, unless domestic law 
provides other appropriate safeguards. 
Subject to sub-paragraph a., the person should also be informed if this information is 
of direct importance to him/her for treatment or prevention 134]. 
2.4. S Conserutltion 
As pointed outin the Explanatory Ivlemorandum [3 5J, as a general nIle, medical data must 
not be stored longer than is strictly necessary," for this could prove to be a threat to the 
data subject's privacy if informat1on relating to any individual is allowed to accumu.1ate 
as the years go by. "However, the interests of public health, scientific research, the 
treating physician, the controUer of the file or historical or statistical reasons may require 
the long term conservation of medical data, even after the death of the persons 
concerned." \Nhen such conservation is necessary appropriate archival security should 
be ensured, 
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2.4.6 Special Provisions 
2.4.6.1 Trrmsbo'rder dtlta flows 
\Vith the increased mobility of people within Europe for employment, business, or other 
reasons the necessity of personal data being exchanged between different nations has 
increased. Furthermore due to the importance of medical data) especially since an 
individual's life may depend on the rapid and uncomplicated communication of his 
medical data and on the other hand the great risk the individual can be exposed to if his 
medical data is not taken care of, the drafters of Rec96 attempted to set out appropriate 
bJllidelines [36Jwithin which data can or should not be transferred (37]. 
2.4.6.2 j\l[ediml Research 
Some of the most effective lobbying on the drafters of the new Recommendation was 
made by members of the medical research community. The latter succeeded in keeping 
their options open when anonymisation of medical data "would make a medical research 
project impossible". In such cases, research could be effected if the data subject has given 
his consent or if the purpose of a defined medical project has been duly authorized, subject 
to non-objection by the data subject. or the research is provided for by law and constitutes 
a necessary measure to protect or promote public health. 
Importantly, healthcare professionals, entitled to carry out their own medical research, 
should be abJe to use medical data which they hold as long as the data subject has been 
informed of this possibility and has not objected. 
2. S Conclusions 
It is impossible to do justice to a complex set of new rnles in such a short space as afforded 
by this paper, which can only attempt to take the reader through the bare outlines of the 
new recomlnendation on the protection of medical data. The new rules described above 
are being proposed to regulate a situation where the reality has shifted from large 
centralized and easily controlled systems to distributed processing with growingly large 
numbers ofPCs which mayor may not be connected to other systems on LAl.'Js, W N'\Ts, 
or via various other means. It is all very well to layout well-intentioned rules on, say, 
transborder clata flows, requiring minimum levels of data protection standards, but are all 
of these rules practical, Jnd therefore enforceable? Can one really police the telephone 
lines to ensure that no transborder How of medical data is Howing to countries which do 
not meet European standards of Data Protection? vVhere does one draw the line between 
effective, reasonable levels of data protection and pious hopes? The LEXI1VIP9 project 
has revealed that only a tiny minority of European states have attempted to translate the 
old 1981 lVledical Data Bank Recommendation into law, let alone enforce the various 
provisions. \Vill Rec96 meet the same fate and remuln, to all intents and purposes, a dead 
letter? A lot of time and effort has been put into the new set of rules but the onus lies on 
the Governments within the member states. Even those states bound by either the ED 
Directive or Convention 108 are not compelled to adopt Rec96 but may choose to rely 
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on their generic legislation to the extent that they may claim this meets their international 
obligations. In the final analysis, however influential, a Recommendation does not have 
the same compelling force as an ED Directive: l\1ember states can nearly afford to ignore 
it. \,\Till they? 
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